MyoKardia, Inc. (NASDAQ:MYOK) Q3 2019 Earnings Conference Call - Final Transcript
Nov 11, 2019 • 08:30 am ET
Ladies and gentlemen thank you for standing by and welcome to the MyoKardia AHA 2019 Data Call.
I would now like to hand the conference over to your speaker today Michelle Corral. Thank you. Please go ahead ma'am.
Thank you, man. Good morning and thank you for joining us for today's call. I'm yourself around my head of corporate communications and Investor Relations. Today we will be reviewing two sets of data. top line data from our phase two Maverick HCM said is now the champion and non obstructed HCM population and the 48-week results from our PIONEER open-label study of mavacamten in obstructive HCM patients. On the MyoKardia website we have posted the 2 press releases issued this morning. Leading today's call is MyoKardia's CEO Tassos Gianakakos. Tassos is joined today by Jay Edelberg our SVP of Clinical Development; and Marc Semigran our SVP of Medical Sciences. Following their prepared remarks we will open the lines for Q&A. As a reminder the information discussed during this call will include forward-looking statements which represent the company's view as of today November 11 2019. We undertake no obligation to update or revise any forward-looking statement to reflect new information or future events except as required by law. Please refer to today's press release as well as our filings with the SEC for information concerning risk factors that could cause actual results to differ materially from those expressed or implied by these statements.
I'd like to now hand the call over to our CEO. Tassos?
Hi everyone and thanks for joining us today. It's an important day for our mavacamten program and for where MyoKardia is heading in HCM and beyond with our precision medicine strategy. Mavacamten continues to generate robust clinical responses in patients with HCM as evidenced by a growing body of data. So this morning we'll be going over new data from 2 studies that continue to paint an increasingly exciting picture for mavacamten's role in HCM patient care. First we'll discuss top line results from our Phase II MAVERICK study in patients with nonobstructive HCM. MAVERICK is one of the largest and most comprehensive studies conducted to date in this patient population. The successful study has provided us a treasure trove of data and new insights about this population whose therapeutic treatment options are virtually nonexistent. We'll also review the 48-week data from our PIONEER-OLE study. After one year of chronic treatment with a once daily pill we're seeing sustained and durable improvements among all patients in the study as well as evidence of some remarkable changes to the structure of the heart.
On behalf of the company, I want to thank the patient's investigators and site staff whose dedication and commitment made the studies of success. We're going to be covering a lot of new information on this call, which will try to do efficiently with some brief headlines before we get into the details starting with Maverick. Maverick primary study objective was demonstrating safety and